Ligand Pharmaceuticals (LGND) Change in Receivables (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Change in Receivables data on file, last reported at -$6.4 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables fell 1212.67% year-over-year to -$6.4 million; the trailing twelve-month figure through Mar 2026 stood at $14.8 million (up 40.54% YoY), and the FY2025 full-year result was $21.7 million, up 236.54% from the prior year.
• Change in Receivables retreated to -$6.4 million in Q1 2026, from $2.1 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $20.4 million in Q2 2022 to a low of -$43.6 million in Q1 2022.
• A 5-year average of -$1.8 million and a median of $576000.0 in 2025 frame the typical range for Change in Receivables.
• Across the five-year window, Change in Receivables slumped 1709.95% in 2022 and soared 757.15% in 2024, its largest moves.
• Tracing LGND's Change in Receivables over 5 years: stood at -$34.8 million in 2022, then soared by 91.85% to -$2.8 million in 2023, then soared by 299.82% to $5.7 million in 2024, then plunged by 63.16% to $2.1 million in 2025, then sank by 407.09% to -$6.4 million in 2026.
• Business Quant data shows LGND's Change in Receivables at -$6.4 million in Q1 2026, $2.1 million in Q4 2025, and $16.3 million in Q3 2025.